Skip to main content

After subcutaneous injection, a majority of patients reported no injection pain (≥75%), no tenderness (≥79%), no erythema (≥92%), and no inflammation (≥88%) after receiving PERSERIS in an 8-week study.1

  • Less than 1% of patients reported moderate tenderness at any time point, and 1 patient reported severe tenderness. Additionally, 1 or 2 patients reported cases of moderate pain, erythema, and/or inflammation/swelling1

Injection site pain was measured using visual analog scale (VAS) (0=no pain to 100=unbearably painful).1

Injection site pain out of 1002

Graph depicting the mean VAS pain scores between 1 and 60 minutes post injection.

See full image description of Injection site pain out of 1002 + -

This graph depicts the mean VAS pain scores for all patients receiving injections (n=500), as well as patients who received 11 injections (n=248) separated by the first and eleventh injection. Pain scores peaked after 1 minute post injection for all cohorts, all decreased at the 5-, 30-, and 60-minute marks. Patients receiving their eleventh injection reported lower pain scores than those experiencing their first injection.

Injection site reactions were measured from the start of the 12-month long-term safety and tolerability study. Rollover patients received 2 prior injections of PERSERIS.2

  • Mean injection site pain VAS scores for all patients (N=500) were 11.2 and 5.6 at 5 minutes and 30 minutes post injection 1, respectively2
  • Mean injection site pain VAS scores for all patients (N=500) 1 minute after injection 1 decreased from ≈25 to ≈16 by injection 11 (N=248)2

Injection site reactions occurring in ≥5% of patients2

  • In an 8-week study, the most common injection site reactions were injection site pain (90 mg: 16%; 120 mg: 22%; placebo: 20%), injection site erythema (90 mg: 6%; 120 mg: 4%; placebo: 5%), and induration/nodule (90 mg: 3%; 120 mg: 3%; placebo: 5%)2
  • In a 12-month long-term safety and tolerability study, the most common injection site reactions for all patients were injection site pain (13%), injection site nodule (7%), injection site induration (6%), and injection site pruritus (5%)2